Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.42 |
| ▸ | USP1 | O94782 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172026 | 1.00 | KCNK3 (0.42) | KCNK3USP1TP53HCRTR1HCRTR2 | |
| SCHEMBL3165821 | 1.00 | KCNK3 (0.42) | KCNK3USP1TP53HCRTR1HCRTR2 | |
| SCHEMBL3547022 | 0.85 | SCD5 (0.52) | TP53HCRTR1HCRTR2 | |
| SCHEMBL3171541 | 0.83 | TP53 (0.51) | TP53HCRTR1HCRTR2NPC1 | |
| SCHEMBL3176891 | 0.81 | KCNK3 (0.41) | KCNK3HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL3166135 | 0.81 | KCNK3 (0.41) | KCNK3HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL3175613 | 0.81 | KCNK3 (0.41) | KCNK3HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL3555052 | 0.80 | SCD5 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL13501713 | 0.79 | SCD (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL3665268 | 0.78 | HCRTR1 (0.39) | HCRTR1HCRTR2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | claimed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | claimed |
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | disclosed |
| EP-2051977-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 | Amgen Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | KCNK3 2772/4885USP1 1623/4885TP53 4444/4885 |
| US-20100022590-A1 | Novel compounds | HSD11B1, CYP11B1, HSD11B2 | KCNK3 1910/4885USP1 969/4885TP53 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.